Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New surgery may prevent ovarian cancer without removing ovaries

NCT ID NCT01608074

Prevention Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a surgery called radical fimbriectomy in women with BRCA mutations who are at high risk for pelvic cancer but want to keep their ovaries. The procedure removes the fallopian tubes, where many of these cancers start, while leaving the ovaries to produce natural hormones. The goal is to prevent cancer while avoiding early menopause. The study includes 123 women aged 35 and older who have completed childbearing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

123 people

The number who actually took part.

Started

Jan 2012

Expected to finish

Aug 2033

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Woman aged over 35 years * When project of childbearing is fulfilled * With a BRCA 1 or 2 mutation, or a family history of breast/ovarian cancer * Unprepared to undergo bilateral annexectomy * With or without breast cancer * Patient affiliated to health insurance * Dated and signed informed consent Exclusion Criteria: * Menopausal woman defined as : Bilateral oophorectomy without hysterectomy and amenorrhea more than 12 months and/or FSH\> 20 UI/l History of hysterectomy and FSH\> 20 UI/l * Pregnant or breastfeeding woman

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRCA1 mutation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

BRCA1-related cancer predisposition BRCA2-related cancer predisposition hereditary breast ovarian cancer syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRCA1 mutation BRCA2 mutation Hereditary breast and ovarian cancer

Contacts and locations

Locations

  • CHR-U

    Lille, France

  • Centre Antoine Lacassagne

    Nice, France

  • Centre Henri Becquerel

    Rouen, France

  • Centre Jean Perrin

    Clermont-Ferrand, France

  • Centre Oscar Lambret

    Lille, France

  • Clinique du Bois - Bourgogne Center

    Lille, France

  • Hospices Civils de Lyon

    Lyon, France

  • Hôpital Privé VA

    Villeneuve-d'Ascq, France

  • IUCT-O Toulouse

    Toulouse, France

  • Institut Bergonié

    Bordeaux, France

  • Institut Curie

    Paris, France

  • Institut Gustave Roussy

    Villejuif, France

  • Institut Paoli Calmettes

    Marseille, France

  • Polyclinique du Parc Rambot

    Aix-en-Provence, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.